Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants
Sponsor: AbbVie
Summary
The main objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single ascending doses of ABBV-701 in healthy adult western and Asian participants.
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Doses of ABBV-701 in Healthy Adult Western and Asian Subjects
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-04-03
Completion Date
2026-11
Last Updated
2026-03-02
Healthy Volunteers
Yes
Conditions
Interventions
ABBV-701
Subcutaneous
Placebo
Subcutaneous
ABBV-701
IV Infusion
Placebo
IV infusion
Locations (2)
CenExel ACT- Anaheim Clinical Trials /ID# 278431
Anaheim, California, United States
Acpru /Id# 273354
Grayslake, Illinois, United States